×

Biotech and Pharmaceuticals Pharmaceuticals

  • Donald Trump

    President Donald Trump on Monday complained that drug prices are too high and said "massive" campaign contributions to Congress are partly to blame.

  • Judge William Bryson issued the ruling in federal court in Marshall, Texas, in a longstanding dispute between Allergan and generic drugmakers Mylan NV, Teva Pharmaceutical Industries Ltd and Akorn Inc.. "What Allergan seeks is the right to continue to enjoy the considerable benefits of the U.S. patent system without accepting the limits that Congress has...

  • Donald Trump

    Barbara Ryan, Barbara Ryan Advisors, discusses President Trump's claims that pharmaceutical companies are "getting away with murder" with prescription drug pricing.

  • Judge William Bryson issued the ruling in federal court in Marshall, Texas, in a longstanding dispute between Allergan and generic drugmakers led by Mylan NV and Teva Pharmaceutical Industries Ltd.. The drug generated around $1.5 billion in sales for Allergan last year and accounted for more than 10 percent of the company's revenue. Senator Claire McCaskill...

  • Oct 16- Shares of pharmaceutical company Allergan Plc dropped on Monday after a ruling by a U.S. judge invalidated patents on its dry eye medicine Restasis on the grounds that the patents cover obvious ideas. Judge William Bryson issued the ruling in federal court in Marshall, Texas, in a longstanding dispute between Allergan and generic drugmakers led by Mylan...

  • Oct 16- A U.S. judge on Monday invalidated patents issued to Allergan Plc on its dry eye medicine Restasis, saying they covered ideas that were too obvious to protect. Judge William Bryson issued the ruling in federal court in Marshall, Texas, in a longstanding dispute between Allergan and generic drugmakers led by Mylan NV and Teva Pharmaceutical Industries...

  • RULING BY FEDERAL JUDGE IN TEXAS IS VICTORY FOR GENERIC DRUGMAKERS MYLAN, TEVA.

  • *Some small consultancies relocating from Britain. LONDON, Oct 16- Drugmakers and medical devices companies are drawing up plans to protect supply chains in case Britain crashes out of the European Union without a trade deal, and some small service businesses are already relocating to stay inside the bloc. "Clearly, if the UK is no longer in the EU, we will be no more...

  • Opioids

    Lenny Bernstein, The Washington Post, talks about the Drug Enforcement Administration's efforts to fight the opioid crisis in America.

  • *Bayer gains after $7 billion disposal; BASF falls. *Profit warning hits UK engineer GKN. LONDON/ MILAN, Oct 13- European shares hit their highest in nearly four months on Friday, helped by gains in Bayer, after the German drugmaker sold assets that will pave the way for its acquisition of Monsanto.

  • ZURICH, Oct 13- Swiss drugmaker Roche's Alecensa has been recommended for approval in Europe as a first-line treatment for mutated lung cancer, a key European Medicines Agency experts panel said on Friday. Zuercher Kantonalbank analyst Michael Nawrath estimates annual sales of Alecensa will hit 1.4 billion Swiss francs by 2024 and capture about 70 percent...

  • BERLIN— German pharmaceutical giant Bayer AG has reached a 5.9 billion euro deal to sell parts of its Crop Science unit to German chemical company BASF to alleviate regulatory concerns over its planned takeover of U.S. seed and weed-killer company Monsanto Co.. Monsanto last year accepted an offer from Bayer to pay $57 billion to its shareholders and assume $9...

  • Oct 12- Allergan Plc said on Thursday it reached a settlement with InnoPharma Inc, one of the four generic drugmakers challenging the patents for its dry eye medication Restasis in federal court. Mylan NV, Teva Pharmaceutical Industries Ltd and Akorn Inc are still contesting those patents in U.S. District Court in Marshall, Texas. Allergan transferred the...

  • Oct 12- The Trump Administration threw its support behind a public-private partnership with 11 drug companies to advance a new class of drugs that uses the body's immune system to fight cancer. The Partnership for Accelerating Cancer Therapies or PACT will devote $215 million to identify and test chemical signatures in the body that will help predict which...

  • Oct 12- The Trump Administration threw its support behind a public-private partnership with 11 drug companies to advance a new class of drugs that uses the body's immune system to fight cancer. The Partnership for Accelerating Cancer Therapies or PACT will devote $215 million to identify and test chemical signatures in the body that will help predict which...

  • A researcher in a Bristol-Myers Squibb laboratory.

    The National Institutes of Health partnered with 11 biopharma companies to advance a new class of drugs that uses the body's immune system to fight cancer.

  • The panel experts to the Food and Drug Administration voted unanimously in favor of Spark Therapeutics' injectable therapy, which aims to improve vision by replacing a defective gene needed to process light. The FDA has until mid-January to make its decision and does not have to follow the panel's recommendation, though it often does. While the therapy from...

  • Oct 12- The National Institutes of Health said on Thursday it had partnered 11 biopharma companies to help advance a new class of drugs that uses the body's immune system to fight cancer. The five-year public-private research collaboration, called Partnership for Accelerating Cancer Therapies, includes drugmakers AbbVie, Roche Holding AG and...

  • ZURICH, Oct 12- Landmark Roche patents that helped launch the modern biotechnology era end next year, extinguishing a source of billions of dollars in income for the Swiss drugmaker and piling pressure on its new medicines to succeed. In 2018 alone, experts estimate the patents will reap $1 billion for Roche and California's City of Hope medical centre, where the...

  • *FDA asks for additional safety data in CRL. *AcelRx says FDA requests "manageable". The FDA last month rejected Intellipharmaceutics International Inc's opioid painkiller, asking for more proof of the drug's ability to prevent abuse.